Julie is 63 years old and has been living with chronic lymphocytic leukaemia
Before initiating cancer therapy, she had recurrent urinary tract infections, herpes zoster and a bronchopneumonia
- Before initiating cancer therapy, she had recurrent urinary tract infections, herpes zoster and a broncopneumonia
- Her partial remission was complicated by symptomatic SID and Julie now requires immunoglobulin replacement therapy
- She is worried that lgG replacement therapy will require more hospital appointments and that it could cause side effects or setbacks in her overall recovery
- Julie will benefit from a reduced risk of hospitalisation and will not need to take as many medications to manage her infections and illness
- The number of patients with needs like Julie's is increasing. This is due to the growing list of immunomodulatory products and the improved outcomes for patients with immunodeficiency disorders, who sometimes require long-term therapy.
References
- Krivan et al. Efficacy, safety and pharmacokinetics of a new 10% normal human immunoglobulin for intravenous infusion, BT595, in children and adults with primary immunodeficiency disease; Vox Sanguinis. 2022;117:1153-1162.